Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
P2Y2 receptor decreases blood pressure by inhibiting ENaC
Antonio G. Soares, … , James D. Stockand, Tarek Mohamed Abd El-Aziz
Antonio G. Soares, … , James D. Stockand, Tarek Mohamed Abd El-Aziz
Published June 6, 2023
Citation Information: JCI Insight. 2023;8(14):e167704. https://doi.org/10.1172/jci.insight.167704.
View: Text | PDF
Research Article Cell biology Nephrology

P2Y2 receptor decreases blood pressure by inhibiting ENaC

  • Text
  • PDF
Abstract

Stimulating the Gq-coupled P2Y2 receptor (P2ry2) lowers blood pressure. Global knockout of P2ry2 increases blood pressure. Vascular and renal mechanisms are believed to participate in P2ry2 effects on blood pressure. To isolate the role of the kidneys in P2ry2 effects on blood pressure and to reveal the molecular and cellular mechanisms of this action, we test here the necessity of the P2ry2 and the sufficiency of Gq-dependent signaling in renal principal cells to the regulation of the epithelial Na+ channel (ENaC), sodium excretion, and blood pressure. Activating P2ry2 in littermate controls but not principal cell–specific P2ry2-knockout mice decreased the activity of ENaC in renal tubules. Moreover, deletion of P2ry2 in principal cells abolished increases in sodium excretion in response to stimulation of P2ry2 and compromised the normal ability to excrete a sodium load. Consequently, principal cell–specific knockout of P2ry2 prevented decreases in blood pressure in response to P2ry2 stimulation in the deoxycorticosterone acetate–salt (DOCA-salt) model of hypertension. In wild-type littermate controls, such stimulation decreased blood pressure in this model of hypertension by promoting a natriuresis. Pharmacogenetic activation of Gq exclusively in principal cells using targeted expression of Gq–designer receptors exclusively activated by designer drugs and clozapine N-oxide decreased the activity of ENaC in renal tubules, promoting a natriuresis that lowered elevated blood pressure in the DOCA-salt model of hypertension. These findings demonstrate that the kidneys play a major role in decreasing blood pressure in response to P2ry2 activation and that inhibition of ENaC activity in response to P2ry2-mediated Gq signaling lowered blood pressure by increasing renal sodium excretion.

Authors

Antonio G. Soares, Jorge Contreras, Elena Mironova, Crystal R. Archer, James D. Stockand, Tarek Mohamed Abd El-Aziz

×

Figure 3

P2ry2 expression in principal cells is necessary for regulation of blood pressure in the DOCA-salt model of hypertension.

Options: View larger image (or click on image) Download as PowerPoint

P2ry2 expression in principal cells is necessary for regulation of bloo...
(A) Summary graph of MAP during the light (L) and dark (D) phases of the day for control littermates (white bars, n = 4 independent trials) and PC-P2ry2–KO mice (black bars, n = 4 independent trials). At all times mice had ad lib access to water. Mice were maintained with normal chow up to and through the beginning of the experiment (day 0). After this day, mice were implanted with DOCA pellets and maintained with an 8% NaCl diet to produce the DOCA-salt model of hypertension. MRS2768 (0.2 mg/kg) was introduced as daily (i.p.) injections on days 9–12. *P < 0.05 vs. control littermates with identical conditions. Summary histograms of MAP (B), SBP (C), and HR (D) for control littermates and PC-P2ry2–KO mice before (basal; white bars; day 0) and after DOCA-salt (black bars; day 8) and the addition of MRS2768 (gray bars; day 12). Data from experiments shown in A. *P < 0.05 within groups vs. basal (day 0) conditions, and #P < 0.05 vs. DOCA-salt, via 2-way ANOVA.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts